Short term news. Note, mid-2014 begins only days away. What can we expect?
Neuren and its joint venture partner Breast Cancer Research Trust are currently exploring strategic options for the anti-cancer programs conducted by Neuren’s subsidiary, Perseis Therapeutics. We expect to provide an outcome from this review by mid-2014.
http://www.neurenpharma.com/IRM/Company/ShowPage.aspx/PDFs/1394-78838394/ChairmansAGMAddresstoShareholders
Also let's not forget this passage from the Preliminary Report...
Reflecting our recalibrated strategic plan and focus on chronic indications for NNZ-2566, the Company is evaluating all strategic options in relation to the further development and commercialisation of the Trefoil Factor programme. This endeavour is currently being supported by Noble Life Sciences.
http://www.neurenpharma.com/IRM/Company/ShowPage.aspx/PDFs/1276-37330793/HalfYearlyReportandAccounts
Note, there are also patents that are pending in the USA, Europe, Japan, China, Australia and New Zealand re Perseis.
Tony
how low can you go?, page-2
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.61 |
Change
0.010(0.06%) |
Mkt cap ! $1.995B | |||
| Open | High | Low | Value | Volume |
| $15.64 | $15.93 | $15.44 | $8.412M | 538.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 558 | $15.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.66 | 1841 | 1 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |